Articles

All Articles

Twitter is a hot start-up that Silicon Valley has been buzzing about for months. It just received a second round of financing. The question is, will it ever make it mainstream or will it remain the darling of the Valley?

Read →

I am not a cardiologist. Just speaking for the millions of individual investors who have been in the market during ups and downs, and who – over time – have put more and more of their assets into equities. These are the folks who enjoy taking risks, but not off-the-wall ones. They are also the ones who are the best candidates for heart attacks on really bad days.

Read →

Why are Americans fascinated by CNBC's Jim Cramer, Jeff Macke and Pete Najarian and what are they telling me to do now?

Read →

There was a time when typewriters were hot and investment in companies like Olivetti, Royal and the like were wise and rich moves. The same today may be said of print media companies. If ever there was writing on the wall, now is the time. The New York Times and the Tribune Company (The Chicago Tribune and others) are engaged in forced cutbacks and greatly curtailed plans as the internet takes away their advertising and news businesses in ever greater chunks. They are fighting back by selling off parts of their companies and making weak entrées into the internet world, but it is a loosing battle. Fewer and fewer people read print papers, more and more people get their news from TV and the internet, and advertisers go in greater and greater numbers – obviously – to where the eyes are.

Read →

Apple absolutely looks fantastic but I am selling. Here is why?

Read →

Qualcomm's earnings report on July 24 looks great. The stock should be much higher. This is one of the few cases with tech stocks where the market is overpricing risk.

Read →

I posted a few days ago about the results of a very concerning meta-analysis (lumping of data from several trials together) suggesting that high dose of cholesterol medicines increase the risk of cancer. This is a huge public health issue which major repercussions for big pharma.

Read →

Consumers spend over $100 million per year on spam email scams. How can anyone still be duped into this? The answer may be a big business opportunity.

Read →
The market is open today and that must mean that Apple is going higher. Same thing with Boeing. Except today is special. Boeing reported stellar earnings in the morning and Apple stellar earnings in the evening. Both stocks seem well on... Read →

Several good reasons why you might want to consider parking your money in several banking stocks instead of the 10 year bond.

Read →

I just saw the first episode of Damages, a corporate law/murder thriller from F/X. It starts Glenn Close and Ted Danson. Here's what I think.

Read →

Angelo Mozilo is a straight shooter and he isn't trying to put a pretty picture on the nation's housing problems.

Read →

China is Coca-Cola's fourth largest market. In the last five years, they have pretty much doubled their sales there. Just imagine what their sales will look like in another five years. To get a handle on growth and forward movement, Coke is investing some $80 million on a R&D center in Shanghai. The US, Brazil and Mexico are Coke's three other major markets. China may well pull ahead soon, and Coke is playing its cards well. Coke is becoming a very good global play.

Read →

Death Bonds, Latest Investment Rage

Just when you thought you had seen the last elegant, complex, and high-risk investment vehicle (I am thinking of all the sub prime machinations), now we have death bonds on the market. These derive from pay-up-front offerings to people... Read →

The results of a large meta-analysis of statin trials were released tonight on CNBC - to be published in JACC - although I don't see it the ACC website and haven't received the journal yet. This hasn't gotten much play yet today - but is potentially huge. This will make doctors and patients question the entire

Read →